Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis.
T StolzeS FrankeJ HaybaeckM MoehlerP P GrimmingerH LangW RothI GockelN KreuserH BläkerC WittekindF LordickM ViethL VeitsO WaidmannP LingohrU PeitzC SchildbergM KruschewskiN VassosE GoniC J BrunsK RidwelskiS WolffH LippertJ SchumacherP MalfertheinerMarino VeneritoPublished in: Journal of cancer research and clinical oncology (2022)
Our data support a positive prognostic effect for MMRd in GC patients treated with surgery only and a differentially negative prognostic effect in patients treated with perioperative chemotherapy. MMR status determined by preoperative biopsies may be used as a predictive biomarker to select patients for perioperative chemotherapy in curatively resectable GC.
Keyphrases
- locally advanced
- patients undergoing
- end stage renal disease
- rectal cancer
- cardiac surgery
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- minimally invasive
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- liver metastases
- coronary artery disease
- coronary artery bypass
- patient reported outcomes
- ultrasound guided
- smoking cessation
- replacement therapy
- liquid chromatography
- free survival
- surgical site infection